Immune
LL-37
Also called Cathelicidin, CAP-18, hCAP18
per administration
Only animal or lab studies exist — no human study has set an amount.
Quick start
LL-37 at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 100–500 mcg per administration
- How often
- Every other day
- Where
- Commonly subcutaneous Sites and rotation
- Time to steady level
- ~3 hours — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for LL-37 describe 100–500 mcg per administration. Descriptive only, not a recommendation.
A cationic antimicrobial peptide degraded by serum proteases; human PK is thin and estimates are rough.
An antimicrobial peptide whose evidence is preclinical; the human dosing literature is absent and circulating amounts are community-derived, so no schedule table is shown.
Modelled level — every other day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 3hours
- Administrations
- 3.5/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Averaged over two weeks
Where these numbers come from
- Cathelicidin / LL-37 antimicrobial literatureHuman cathelicidin biology and in-vitro antimicrobial work; injectable human amounts are community-derived, not established.